IP Library › Granted Patent US 12,239,442
Granted Patent B2
US 12,239,442 · App. 17/348,169 · Granted Mar 4, 2025

Analyte sensors with reduced interferent signal and methods

Inventors: Udo Hoss (San Ramon, CA); Tianmei Ouyang (Fremont, CA); Benjamin J. Feldman (Berkeley, CA); Suyue Qian (Fremont, CA)
Assignee: ABBOTT DIABETES CARE INC.
A61B5/14865A61B5/14532A61B2562/125
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,239,442
App. No.
17/348,169
Granted
Mar 4, 2025
Kind
B2
Abstract

Analyte sensor comprises an electrode layer having an elongate body comprising a proximal end and a distal end. The electrode layer includes a first active working electrode area, a second electrode portion, and at least one gap electrically separating the first active working electrode portion and the second electrode portion. The first active working electrode area comprises at least one sensing spot with at least one analyte responsive enzyme disposed thereupon. Additional analyte sensors disclosed.

Claims (41)

1. An analyte sensor comprising: a working electrode including a working electrode layer having an elongate body comprising a proximal end and a distal end, the working electrode layer including a first active working electrode area, a second electrode portion, and at least one channel or well formed in the working electrode layer and electrically separating the first active working electrode area and the second electrode portion; and one or more additional electrodes, wherein the one or more additional electrodes comprise a counter electrode, a reference electrode, or both; and wherein the first active working electrode area comprises at least one sensing spot with at least one analyte responsive enzyme disposed thereupon and configured to generate a signal associated with an analyte of interest, wherein the second electrode portion is configured to reduce an overall interference to the signal attributed to one or more interferents.

2. The analyte sensor of claim 1 , wherein the first active working electrode area comprises a plurality of sensing spots.

3. The analyte sensor of claim 2 , wherein first and second adjacent sensing spots in the first active working electrode area are in an overlapping configuration.

4. The analyte sensor of claim 3 , wherein third and fourth adjacent sensing spots in the first active working electrode area are in an overlapping configuration.

5. The analyte sensor of claim 3 , wherein all the plurality of sensing spots in the first active working electrode area are in an overlapping configuration.

6. The analyte sensor of claim 3 , wherein a shape of each of the plurality of sensing spots is at least one of spherical, circular, square, rectangular, triangular, conical, or elliptical, or a combination thereof.

7. The analyte sensor of claim 3 , wherein first, second, and third sensing spots in the first active working electrode area are in an overlapping configuration.

8. The analyte sensor of claim 3 , wherein the plurality of sensing spots in the first active working electrode area are in a linear configuration.

9. The analyte sensor of claim 3 , wherein the plurality of sensing spots in the first active working electrode area are in a non-linear configuration.

10. The analyte sensor of claim 3 , wherein the plurality of sensing spots in the first active working electrode area are in a grid configuration.

11. The analyte sensor of claim 3 , wherein the at least one analyte responsive enzyme disposed upon the plurality of sensing spots of the first active working electrode area is a glucose responsive enzyme.

12. The analyte sensor of claim 1 , wherein the at least one analyte responsive enzyme disposed on the at least one sensing spot of the first active working electrode area is a glucose responsive enzyme.

13. The analyte sensor of claim 1 , wherein the at least one channel or well in the working electrode layer is U-shaped and extends from the proximal end of the elongate body on a first side of the first active working electrode area to proximate distal end of the elongate body of the working electrode layer, and back to the proximal end of the elongate body on a second side of the first active working electrode area.

14. The analyte sensor of claim 1 , wherein the at least one channel or well comprises two laterally spaced apart gaps extending from the proximal end of the elongate body of the working electrode layer to the distal end of the elongate body of the working electrode layer on opposing sides of the first active working electrode area.

15. The analyte sensor of claim 1 , wherein the at least one channel or well in the working electrode layer comprises a wavy pattern, a curly pattern, a curvy pattern, an undulating pattern, or a crimped pattern.

16. The analyte sensor of claim 1 , wherein the at least one channel or well in the working electrode layer has a width of 1 μm to 100 μm and electrically insulates the first working electrode from the second electrode portion.

17. The analyte sensor of claim 1 , wherein the at least one channel or well is formed in the working electrode layer during fabrication of the working electrode layer.

18. The analyte sensor of claim 1 , wherein the at least one channel or well is laser-cut in the working electrode layer.

19. The analyte sensor of claim 1 , wherein the first active working electrode area is connected to a first sensor current conductive trace and the second electrode portion of the electrode layer is not connected to a sensor current conductive trace.

20. The analyte sensor of claim 1 , wherein the first active working electrode area is connected to a first sensor current conductive trace and the second electrode portion of the electrode layer is connected to a second sensor current conductive trace.

21. The analyte sensor of claim 20 , wherein the second electrode portion is a scrubbing electrode configured to oxidize one or more interferents.

22. The analyte sensor of claim 21 , wherein the interferent is selected from a group consisting of ascorbic acid, glutathione, uric acid, acetaminophen, isoniazid, salicylate, and combinations thereof.

23. The analyte sensor of claim 22 , wherein the interferent is ascorbic acid.

24. The analyte sensor of claim 1 , comprising:

a substrate, wherein the working electrode layer is disposed on the substrate; and

an interferent-barrier membrane layer disposed upon at least a portion of the sensor and comprising sulfonated tetrafluoroethylene based fluoropolymer, the interferent barrier-membrane configured to reduce an interferent signal of at least one interferent.

25. The analyte sensor of claim 24 , further comprising a second membrane layer disposed upon the working electrode layer and the interferent-barrier membrane layer is disposed upon the second membrane layer.

26. The analyte sensor of claim 25 , wherein the second membrane layer comprises polyvinylpyridine homopolymer or copolymer.

27. The analyte sensor of claim 26 , wherein the at least one interferent is selected from a group consisting of ascorbic acid, glutathione, uric acid, acetaminophen, isoniazid, salicylate, and combinations thereof.

28. The analyte sensor of claim 27 , wherein the interferent is ascorbic acid.

29. The analyte sensor of claim 28 , wherein the interferent signal is reduced to 5% or less of a total signal when an electrode potential is in the range of −100 mV to +100 mV.

30. The analyte sensor of claim 29 , wherein the at least one analyte responsive enzyme disposed on the at least one sensing spot of the first active working electrode area is a glucose responsive enzyme.

31. The analyte sensor of claim 28 , wherein the interferent signal is reduced to 3% or less of a total signal when an electrode potential is in the range of −80 mV to +80 mV.

32. The analyte sensor of claim 25 , wherein the interferent-barrier membrane layer is coated on the second membrane layer.

33. An analyte sensor comprising: a substrate having an upper surface comprising a first portion and a second exposed portion; a working electrode including a working electrode layer disposed upon the first portion of the upper surface of the substrate, the working electrode layer including an in vivo portion having a first active working electrode area comprising at least one sensing spot with at least one analyte-responsive enzyme disposed thereupon, a second electrode portion, and at least one channel or well electrically separating the first active working electrode area and the second electrode portion, wherein the second electrode portion is configured to reduce an overall interference to the signal attributed to one or more interferents; one or more additional electrodes, wherein the one or more additional electrodes comprise a counter electrode, a reference electrode, or both; and a membrane covering at least a portion of the working electrode layer and the second exposed portion of the upper surface of the substrate.

34. The analyte sensor of claim 33 , wherein the substrate comprises a polymeric material selected from polyester, or polyimide.

35. The analyte sensor of claim 34 , wherein the polymeric material is polyester.

36. The analyte sensor of claim 33 , wherein at least a portion of the second exposed portion of the upper surface of the substrate is roughened.

37. The analyte sensor of claim 33 , wherein the membrane comprises a material selected from a polymeric material, a cross-linking agent, and combinations thereof.

38. The analyte sensor of claim 37 , wherein the polymeric material comprises polyvinylpyridine homopolymer or copolymer.

39. The analyte sensor of claim 33 , wherein the at least one analyte responsive enzyme disposed upon the sensing spot of the first active working electrode area is a glucose responsive enzyme.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2021
From: HOSS, UDO; OUYANG, TIANMEI; FELDMAN, BENJAMIN J.; QIAN, SUYUE
To: ABBOTT DIABETES CARE INC.
Reel/Frame 056550/0663 →
Continuity (2)
Provisional Application 63129874 · Dec 23, 2020
Related Publication 20220192550A1 · Jun 23, 2022
References Cited (232)
US 5089112A · Skotheim et al. · 1992 [cited by applicant]
US 5165407A · Wilson et al. · 1992 [cited by applicant]
US 5322063A · Allen et al. · 1994 [cited by applicant]
US 5390671A · Lord et al. · 1995 [cited by applicant]
US 5569186A · Lord et al. · 1996 [cited by applicant]
US 5584813A · Livingston et al. · 1996 [cited by applicant]
US 5849174A · Sanghera et al. · 1998 [cited by applicant]
US 6103033A · Say et al. · 2000 [cited by applicant]
US 6134461A · Say et al. · 2000 [cited by applicant]
US 6237394B1 · Harris et al. · 2001 [cited by applicant]
US 6424847B1 · Mastrototaro et al. · 2002 [cited by applicant]
US 6565509B1 · Say et al. · 2003 [cited by applicant]
US 6605200B1 · Mao et al. · 2003 [cited by applicant]
US 6605201B1 · Mao et al. · 2003 [cited by applicant]
US 6673022B1 · Bobo et al. · 2004 [cited by applicant]
US 6736957B1 · Forrow et al. · 2004 [cited by applicant]
US 6809653B1 · Mann et al. · 2004 [cited by applicant]
US 6850859B1 · Schuh · 2005 [cited by applicant]
US 6931327B2 · Goode, Jr. et al. · 2005 [cited by applicant]
US 6990366B2 · Say et al. · 2006 [cited by applicant]
US 7299082B2 · Feldman et al. · 2007 [cited by applicant]
US 7323142B2 · Pendo et al. · 2008 [cited by applicant]
US 7501053B2 · Karinka et al. · 2009 [cited by applicant]
US 7725148B2 · Shah et al. · 2010 [cited by applicant]
US 7754093B2 · Forrow et al. · 2010 [cited by applicant]
US 8268143B2 · Liu et al. · 2012 [cited by applicant]
US 8280474B2 · Liu et al. · 2012 [cited by applicant]
US 8444834B2 · Liu et al. · 2013 [cited by applicant]
US 8983568B2 · Bommakanti et al. · 2015 [cited by applicant]
US 9241631B2 · Valdes et al. · 2016 [cited by applicant]
US 9504471B2 · Vaitekunas et al. · 2016 [cited by applicant]
US 9788766B2 · Simpson et al. · 2017 [cited by applicant]
US 9808574B2 · Yodfat et al. · 2017 [cited by applicant]
US 10820842B2 · Harper · 2020 [cited by applicant]
US 10827954B2 · Hoss et al. · 2020 [cited by applicant]
US 10874338B2 · Stafford · 2020 [cited by applicant]
US 10881341B1 · Curry et al. · 2021 [cited by applicant]
US 10945647B2 · Mazza et al. · 2021 [cited by applicant]
US 10945649B2 · Lee et al. · 2021 [cited by applicant]
US 10952653B2 · Harper · 2021 [cited by applicant]
US 10959654B2 · Curry et al. · 2021 [cited by applicant]
US 10966644B2 · Stafford · 2021 [cited by applicant]
US 10973443B2 · Funderburk et al. · 2021 [cited by applicant]
US 10980461B2 · Simpson et al. · 2021 [cited by applicant]
US 11000213B2 · Kamath et al. · 2021 [cited by applicant]
US 11000216B2 · Curry et al. · 2021 [cited by applicant]
US 11013440B2 · Lee et al. · 2021 [cited by applicant]
US 11064917B2 · Simpson et al. · 2021 [cited by applicant]
US 11141084B2 · Funderburk et al. · 2021 [cited by applicant]
US 20020161288A1 · Shin et al. · 2002 [cited by applicant]
US 20020169369A1 · Ward et al. · 2002 [cited by applicant]
US 20030042137A1 · Mao et al. · 2003 [cited by applicant]
US 20030097082A1 · Purdy et al. · 2003 [cited by applicant]
US 20030114836A1 · Estes et al. · 2003 [cited by applicant]
US 20030225361A1 · Sabra · 2003 [cited by applicant]
US 20040061232A1 · Shah et al. · 2004 [cited by applicant]
US 20040087876A1 · Eskuri · 2004 [cited by applicant]
US 20050027181A1 · Goode, Jr. et al. · 2005 [cited by applicant]
US 20050038332A1 · Saidara et al. · 2005 [cited by applicant]
US 20050215871A1 · Feldman et al. · 2005 [cited by applicant]
US 20050245799A1 · Brauker et al. · 2005 [cited by applicant]
US 20060020187A1 · Brister et al. · 2006 [cited by applicant]
US 20060094944A1 · Chuang · 2006 [cited by applicant]
US 20060142651A1 · Brister et al. · 2006 [cited by applicant]
US 20060200982A1 · Bhullar et al. · 2006 [cited by applicant]
US 20060257996A1 · Simpson et al. · 2006 [cited by applicant]
US 20060258959A1 · Sode · 2006 [cited by applicant]
US 20080161666A1 · Feldman et al. · 2008 [cited by applicant]
US 20080172205A1 · Breton et al. · 2008 [cited by applicant]
US 20080194990A1 · Heller et al. · 2008 [cited by applicant]
US 20080319414A1 · Yodfat et al. · 2008 [cited by applicant]
US 20090076360A1 · Brister et al. · 2009 [cited by applicant]
US 20090099521A1 · Gravesen et al. · 2009 [cited by applicant]
US 20090102678A1 · Mazza et al. · 2009 [cited by applicant]
US 20090178459A1 · Li et al. · 2009 [cited by applicant]
US 20100145377A1 · Lai et al. · 2010 [cited by applicant]
US 20100193484A1 · Chen et al. · 2010 [cited by applicant]
US 20100230285A1 · Hoss et al. · 2010 [cited by applicant]
US 20100286496A1 · Simpson et al. · 2010 [cited by applicant]
US 20110213225A1 · Bernstein et al. · 2011 [cited by applicant]
US 20120150005A1 · Hoss et al. · 2012 [cited by applicant]
US 20130345534A1 · Hoss · 2013 [cited by examiner]
US 20150005601A1 · Hoss et al. · 2015 [cited by applicant]
US 20150094554A1 · Heller et al. · 2015 [cited by applicant]
US 20150298124A1 · Fischer et al. · 2015 [cited by applicant]
US 20150351690A1 · Toth et al. · 2015 [cited by applicant]
US 20160235347A1 · Baig et al. · 2016 [cited by applicant]
US 20170107555A1 · Katsuki et al. · 2017 [cited by applicant]
US 20170112531A1 · Schoonmaker et al. · 2017 [cited by applicant]
US 20170188908A1 · Hoss et al. · 2017 [cited by applicant]
US 20170265795A1 · Boock et al. · 2017 [cited by applicant]
US 20170273610A1 · Suri et al. · 2017 [cited by applicant]
US 20170363564A1 · Hoss et al. · 2017 [cited by applicant]
US 20180199873A1 · Wang et al. · 2018 [cited by applicant]
US 20180328877A1 · Vaddiraju et al. · 2018 [cited by applicant]
US 20190125230A1 · Feldman · 2019 [cited by applicant]
US 20190175083A1 · Cohen et al. · 2019 [cited by applicant]
US 20190216374A1 · Hoss et al. · 2019 [cited by applicant]
US 20190261907A1 · Brister et al. · 2019 [cited by applicant]
US 20190298232A1 · Ko · 2019 [cited by examiner]
US 20190310222A1 · Boock · 2019 [cited by applicant]
US 20190320947A1 · Chen et al. · 2019 [cited by applicant]
US 20190326501A1 · Gilbert et al. · 2019 [cited by applicant]
US 20200022670A1 · Eibl et al. · 2020 [cited by applicant]
US 20200060592A1 · Feldman et al. · 2020 [cited by applicant]
US 20200146595A1 · Simpson et al. · 2020 [cited by applicant]
US 20200178862A1 · Brister · 2020 [cited by applicant]
US 20200178864A1 · Cui et al. · 2020 [cited by applicant]
US 20200237275A1 · Feldman et al. · 2020 [cited by applicant]
US 20200237277A1 · Ouyang et al. · 2020 [cited by applicant]
US 20200241015A1 · Ouyang et al. · 2020 [cited by applicant]
DK PA200401265 · 2004 [cited by applicant]
EP 0838230A2 · 1998 [cited by applicant]
GB 2067764A · 1981 [cited by applicant]
WO WO9856293A1 · 1998 [cited by applicant]
WO WO9956613A1 · 1999 [cited by applicant]
WO WO03056319A2 · 2003 [cited by applicant]
WO WO2004088275A2 · 2004 [cited by applicant]
WO WO2006018447A2 · 2006 [cited by applicant]
WO WO2006042811A2 · 2006 [cited by applicant]
WO WO2010091005A1 · 2010 [cited by applicant]
Chen et al., “Defining the Period of Recovery of the Glucose Concentration after Its Local Perturbation by the Implantation of a Miniature Sensor,” Clin Chem Lab Med 40(8):786-789 (2002). [cited by applicant]
DCU Conferences, Nov. 2003, 8 pgs. [cited by applicant]
Declaration of John Mastrototaro, PH.D., 205 pgs. (Sep. 29, 2022). [cited by applicant]
Dexcom 10K, 59 pgs. (2005). [cited by applicant]
DexCom CGM Resource Center References Bibliography, 14 pgs. (Jun. 12, 2011). [cited by applicant]
Dexcom SEC Form, S-1-2005, 309 pgs. (Feb. 1, 2005). [cited by applicant]
Diabetes Abstract Book, 53(2):1-12 (Jun. 2004). [cited by applicant]
FDA Notice—Determination of Regulatory, Federal Registry 86(211):60827-60829 (Nov. 4, 2021) 3 pgs. [cited by applicant]
FDA Premarket Approval (PMA) for Freestyle Navigator Continuous Glucose Monitor, Jan. 23, 2022, 6 pgs. [cited by applicant]
Feldman et al., “A Continuous Glucose Sensor Based on Wired Enzyme Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes,” Diabetes Technology & Thgerapeutics 5(5):769-779 (2003). [cited by applicant]
Freestyle Navigator User Guide, (Mar. 6, 2000) 38 pgs. [cited by applicant]
Heinemann et al., “Benefits and Limitations of MARD as a Performance Parameter for Continuous Glucose Monitoring in the Interstitial Space,” Journal of Diabetes Science and Technology 14(1):135-150 (2020). [cited by applicant]
Heller et al., “Electrochemical Glucose Sensors and Their Applications in Diabetes Management,” Chem. Rev. 108:2482-2505 (2008). [cited by applicant]
Heller et al., “Electrochemistry in Diabetes Management,” Accounts of Chemical Research 43(7):963-973 (2010). [cited by applicant]
Heller, “Integrated Medical Feedback Systems for Drug Delivery,” AIChE Journal 51(4):1054-1066 (2005). [cited by applicant]
International Search Report and Written Opinion mailed Sep. 24, 2021 in International Application No. PCT/US2021/037307. [cited by applicant]
International Search Report and Written Opinion mailed Sep. 24, 2021 in International Application No. PCT/US2021/037309. [cited by applicant]
International Search Report and Written Opinion mailed Sep. 23, 2021 in International Application No. PCT/US2021/037313. [cited by applicant]
International Search Report and Written Opinion mailed Sep. 24, 2021 in International Application No. PCT/US2021/037322. [cited by applicant]
Kovatchev et al., “Evaluating the Accuracy of Continuous Glucose-Monitoring Sensors,” Diabetes Care 27:1922-1928 (2004). [cited by applicant]
Original Premarket Approval Application (Jun. 2005), 61 pgs. [cited by applicant]
Premarket Approval Application Amendment (May 2006), 89 pgs. [cited by applicant]
Reiterer et al., “Significance and Reliability of MARD for the Accuracy of CGM Systems,” Journal of Diabetes Science and Technology 11(1):59-67 (2017). [cited by applicant]
Therasense Navigates Continuous Glucose Monitor PMA, Prepares for Flash, The Gray Sheet 29(37):18 (2003), 2 pgs. [cited by applicant]
Ward et al., “A Wire-Based Dual-Analyte Sensor for Glucose and Lactate: In Vitro and In Vivo Evaluation,” Diabetes Technology & Therapeutics 6(3):389-401 (2004). [cited by applicant]
Website—Abbotts Continuous Blood Glucose Monitor Approval Soon, Oct. 3, 2006, 3 pgs. [cited by applicant]
Website—Children w Diabetes-Report from Diabetes Tech, Jan. 21, 2022, 3 pgs. [cited by applicant]
Website—Dexcom Leading the Way Brochure, 2009, 12 pgs. [cited by applicant]
Website—TheraSense Files Premarket Approval Application for Freestyle Navigator, Dec. 13, 2003, 3 pgs. [cited by applicant]
Wilson et al., “Introduction to the Glucose Sensing Problem,” Chapter 1 (2010) 27 pgs. [cited by applicant]
U.S. Appl. No. 17/347,829, filed Jun. 15, 2021. [cited by applicant]
U.S. Appl. No. 17/347,869, filed Jun. 15, 2021. [cited by applicant]
U.S. Appl. No. 17/347,845, filed Jun. 15, 2021. [cited by applicant]
Khan et al., “Kinetics of the reduction of water-soluble colloidal MnO2 by ascorbic acid,” Journal of Colloid and Interface Science 290:184-189 (2005). [cited by applicant]
U.S. Appl. No. 60/490,208, filed Jul. 25, 2003, Simpson. [cited by applicant]
U.S. Appl. No. 17/347,869, filed Oct. 25, 2022 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 17/347,845, filed Dec. 22, 2022 Non-Final Office Action. [cited by applicant]
Cho et al., “The TheraSense, Inc. Continuous Glucose Monitor: Preliminary Clinical Results from a Subcutaneous Sensor with a Wireless Connection to a Hand-Held Display/Alarm,” Clinical Therapeutics/New Technology—Glucos… [cited by applicant]
Craston et al., “Microband Electrodes Fabricated by Screen Printing Processes: Applications in Electroanalysis,” Talanta, vol. 38, No. 1, 17-26 (1991). [cited by applicant]
“Abbott Receives CE Mark for Freestyle® Libre, A Revolutionary Glucose Monitoring System for People with Diabetes,” 8 pages (2023). [cited by applicant]
“FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices,” FDA News Release, retrieved from https://www.fda.gov/news-events/press-announcements/fda-a… [cited by applicant]
ATTD Program, 4 pages (2009). [cited by applicant]
Cambridge Dictionary of American English, 3 pages (2000)—Recess. [cited by applicant]
Dexcom (DXCM) Company Profile, 2017 /Q4 Earnings call transcript, 12 pages (2017). [cited by applicant]
DexCom (DXCM) Q1 2018 Results—Earnings Call Transcriptretrieved from https://seekingalpha.com/article/4168949-dexcom-dxcm-q1-2018-results-earnings-call-transcript on May 2, 2018, 4 pages. [cited by applicant]
Dexcom G6 Continuous Glucose Monitoring System User Guide, 7 pages (2020). [cited by applicant]
Dexcomg6, Continuous Glucose Monitoring System, User Guide, 22 pages (2020). [cited by applicant]
Dexcomg6, Start Here, Set up, Dexcom G6 Continuous Glucose Monitoring (CGM) System (G6), 8 pages (2019). [cited by applicant]
Dexcomg6, Using Your G6, 7 pages (2020). [cited by applicant]
Drawing Sheets for U.S. Pat. No. 10,973,443 issued Apr. 13, 2021, 2 pages. [cited by applicant]
Email communication from Sophie Hood, Jan. 24, 2023, 6 pages. [cited by applicant]
Excerpts from Expert Report of Catharine M. Lawton—Ex. 36, Spruce Point Capital Management, Does Dexcom Really Have A Future If It Can't Match Abbott's Scale? 2 pages, Mar. 21, 2019. [cited by applicant]
Hall, Interview with Kevin Sayer, President and CEO of Dexcom About The New Dexcom G6, College Diabetes Network, 6 pages (2021). [cited by applicant]
Hoss et al., “Continuous glucose monitoring in the tissue: Do we really need to calibrate in-vivo?,” Diabetes Technology & Therapeutics, vol. 11, No. 2, 23 pages (2009). [cited by applicant]
Hoss, et al., “Continuous Glucose Monitoring in Subcutaneous Tissue Using Factory—Calibrated Sensors: A Pilot Study”, Diabetes Technology & Therapeutics, 12(8):591-597 (2010). [cited by applicant]
Hoss, et al., “Feasibility of Factory Calibration for Subcutaneous Glucose Sensors in Subjects With Diabetes”, Journal of Diabetes Science and Technology, 8(1):89-94 (2014). [cited by applicant]
IEEE 100, The Authoritative Dictionary of IEEE Standards Terms, 7 [cited by applicant]
Interview with Dexcom CEO, Dexcom CEO Kevin Sayer Explains G6, Written By: Michelle Boise, 9 pages (2018). [cited by applicant]
Joint Declaration of Funderburk, et al. for U.S. Appl. No. 15/963,828, 11 pages (2020). [cited by applicant]
Letter from the Department of Health & Human Services, Food and Drug Administration to Abbott Diabetes Care, Inc. dated Mar. 12, 2008, regarding the Premarket Approval Application (PMA) for the FreeStyle Navigator Conti… [cited by applicant]
Merriam-Webster's Collegiate Dictionary, 10 [cited by applicant]
Merriam-Webster's Collegiate Dictionary, 10 [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 14/884,622 dated Jun. 13, 2018, 7 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/030,030 dated Dec. 17, 2020, 7 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/963,828 dated Mar. 3, 2021, 32 pages. [cited by applicant]
Omnipod image, Exhibit 182, 2 pages, Sep. 22, 2022. [cited by applicant]
Response to Non-Final Office Action for U.S. Appl. No. 15/963,828, filed Dec. 8, 2020, 17 pages. [cited by applicant]
Response to Restriction Requirement for U.S. Appl. No. 14/884,622, filed Apr. 5, 2018, 15 pages. [cited by applicant]
S&P Global Market Intelligence “DeXCom, Inc. NasdaqGS:DXCM, Company Conference Presentation,” 17 pages (2021). [cited by applicant]
S&P Global Market Intelligence “DeXCom, Inc. NasdaqGS:DXCM, Company Conference Presentation,” 10 pages (2020). [cited by applicant]
S&P Global Market Intelligence “DexCom, Inc. NasdaqGS:DXCM, Company Conference Presentation,” 11 pages (2019). [cited by applicant]
Sayer, CGMS Changing Diabetes Management: Kevin Sayer, DIC Interview Transcript, Featuring Steve Freed, 11 pages (2019). [cited by applicant]
Sonix, Dexcom CEO—Prime Position in Our Market—Mad Money—CNBC.mp4, 4 pages (2023). [cited by applicant]
Tegnestedt, et al., “Levels and sources of sound in the intensive care unit—an observational study of three room types”, Acta Anaesthesiologica Scandinavica, pp. 1-10 (2013). [cited by applicant]
The Chambers Dictionary, 4 pages (1998)—Retract. [cited by applicant]
The MiniMed Paradigm® REAL-Time Insulin Pump and Continuous Glucose Monitoring System, Insulin Pump User Guide, Paradigm® 522 and 722 Insulin Pumps, Medtronic MiniMed, Inc., 25 pages (2008). [cited by applicant]
The New Oxford American Dictionary, 3 pages (2001)—Retract. [cited by applicant]
The New Penguin English Dictionary, Penguin Books, 4 pages (2000)—Recess. [cited by applicant]
U.S. Food & Drug Administration, “Deciding When to Submit a 510(k) for a Change to an Existing Device, Guidance for Industry and Food and Drug Administration Staff,” 78 pages (2017). [cited by applicant]
U.S. Food & Drug Administration, “Deciding When to Submit a 510(k) for a Software Change to an Existing Device, Guidance for Industry and Food and Drug Administration Staff,” 32 pages (2017). [cited by applicant]
Watkin, “An Introduction to Flash Glucose Monitoring,” 16 pages (2013). [cited by applicant]
Webster's New College Dictionary, 2 pages (2001)—Alcove. [cited by applicant]
Webster's Third New International Dictionary, 5 pages (1993)—Retract. [cited by applicant]
Chen, et al., “A novel fault-tolerant sensor system for sensor drift compensation”, Sensors and Actuators, A 147:623-632 (2008). [cited by applicant]
FreeStyle Navigator Continuous Glucose Monitoring System, Summary of Safety and Effectiveness Data in support of Pre-Market Approval (PMA) No. P050020, Abbott Diabetes Care, 27 pages (2008). [cited by applicant]
FreeStyle Navigator Continuous Glucose Monitoring System, User Guide, Abbott Diabetes Care Inc., 195 pages (2008). [cited by applicant]
Gerritsen, et al., “Performance of subcutaneously implanted glucose sensors for continuous monitoring”, The Netherlands Journal of Medicine, 54:167-179 (1999). [cited by applicant]
Guardian® Real-Time, Continuous Glucose Monitoring System, User Guide, Medtronic MiniMed, Inc., 181 pages (2006). [cited by applicant]
Guardian® RT, Continuous Glucose Monitoring System, REF MMT-7900, User Guide, Medtronic MiniMed, 128 pages (2005). [cited by applicant]
Kalivas, et al., “Compensation for Drift and Interferences in Multicomponent Analysis”, Laboratory for Chemometrics, Department of Chemistry, University of Washington, 38 pages (1982). [cited by applicant]
Thévenot, et al., “Electrochemical Biosensors: Recommended Definitions and Classification (Technical Report)”, Pure Appl. Chem. 71(12):2333-2348 (1999). [cited by applicant]
U.S. Appl. No. 12/842,013 Office Action mailed Aug. 26, 2015. [cited by applicant]
U.S. Appl. No. 12/842,013 Office Action mailed Mar. 23, 2016. [cited by applicant]
U.S. Appl. No. 12/842,013 Office Action mailed Nov. 6, 2014. [cited by applicant]
Walt, et al., “The chemistry of enzyme and protein immobilization with glutaraldehyde”, Trends in Analytical Chemistry, 13(10):425-430 (1994). [cited by applicant]
Zhang, “Investigations of potentially implantable glucose sensors”, University of Kansas, 24 pages (1991). [cited by applicant]
U.S. Appl. No. 61/155,889, filed Feb. 26, 2009, Hoss, et al. [cited by applicant]
Brückel, et al., “In Vivo Measurement of Subcutaneous Glucose Concentrations with an Enzymatic Glucose Sensor and a Wick Method”, Klin Wochenschr, 67:491-495 (1989). [cited by applicant]
U.S. Appl. No. 61/155,889. [cited by applicant]
FreeStyle Navigator Continuous Glucose Monitoring System, User's Guide, Abbott Diabetes Care Inc., 38 pages (2008). [cited by applicant]
Guardian® REAL-Time, Continuous Glucose Monitoring System, User Guide, Medtronic MiniMed, Inc., 184 pages (2006). [cited by applicant]
Mastrototaro, et al., “An electroenzymatic glucose sensor fabricated on a flexible substrate”, Sensors and Actuators B, 5:139-144 (1991). [cited by applicant]
FreeStyle Navigator Continuous Glucose Monitoring System, Dept of Health & Human Services, Food and Drug Administration, Mar. 12, 2008, 8 pages. [cited by applicant]
U.S. Appl. No. 17/347,829, filed Nov. 8, 2023 Final Office Action. [cited by applicant]
U.S. Appl. No. 17/347,845, filed Nov. 22, 2023 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 17/347,869, filed Dec. 7, 2023 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 17/347,869, filed Jun. 10, 2024 Final Office Action. [cited by applicant]
U.S. Appl. No. 17/347,829, filed Apr. 11, 2024 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 17/347,829, filed Sep. 26, 2024 Final Office Action. [cited by applicant]
U.S. Appl. No. 17/347,845, filed Apr. 9, 2024 Final Office Action. [cited by applicant]
U.S. Appl. No. 17/347,845, filed Aug. 5, 2024 Non-Final Office Action. [cited by applicant]